Watching and Learning!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ECTE is holding decently down here, they really need to see a pop soon. They have taken a long time to bring something to market and just havent got it done. Wish everyone good luck here.
ECTE may be a good buy at these prices.....but look at where this was a year ago....be careful.....been there, done that with others...painful
I thought this stock was done and I didn't realize that they cannot get their product done. I didnt think it would go back down this far. Sorry guys
This one just is making any progress. They something definitive that brings in CASH
About time Knight got what they deserve!
this seems to be the majority of penny stocks. Very few real companies that do anything real. I would advise anyone to stick to at least the nasdaq.
Looks like this one is almost done. It did go a lot higher than I thought it would. This was really promoted. I would sell now and there is no shorting.
I have no dog in this hunt; I would be very leary of this stock and I would get out ASAP. This looks as dangerous as some stocks I was in ( CDIV, EIGH). I didn't listen and lost a lot.
Moving up steadily.
Very interesting move today. Maybe a picture of things to come.
Don't see where this is going short term.
FDA approval and start of change for diabetics forever.
In six months, this will look great compared to much bigger stocks today.
Lucky day, I sold out at an old order of $2.28. Shorts are definitely going to do some strange things here.
Great time to buy or add here. Should be back to 4 dollar range soon.
Great interview on a fund manager on a stock show on Bloomberg radio. Great company with great products coming and/or a great pharmaceutical buyout opportunity. HOLD for one year.
IMHO
Echo Therapeutics Announces Multiple Patents and Trademark Grants
print
Echo Therapeutics, Inc. (MM) (NASDAQ:ECTE)
Intraday Stock Chart
Today : Monday 8 August 2011
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphonyâ„¢ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Preludeâ„¢ SkinPrep System for transdermal drug delivery, today announced the receipt of notices of issuance for two patents covering its Symphony tCGM System and notices of registration for the trademarks PRELUDE and SYMPHONY.
Echo Therapeutics received notice that its patent application entitled, "System and Method for Continuous Non-Invasive Glucose Monitoring" will issue as U.S. Patent No. 7,963,917. As a result of a patent term adjustment that is expected to add nearly 4 years to the term of the patent, it is expected to expire in 2025. Echo Therapeutics also received notice that its patent application entitled "Transdermal Analyte for Monitoring Systems and Methods for Analyte Detection" was issued as South Africa Patent No. 2009/06959 and will expire in 2028. Additionally, Echo has received notice that its applications for the trademark PRELUDE have been registered for use in International Class 10 in South Korea and Mexico; and its application for the trademark SYMPHONY has been registered for use in International Class 10 in Israel.
"We have long recognized the unique value that our non-invasive, glucose monitoring technology can provide, and these patents reinforce this belief, further demonstrating the proprietary nature of our technology," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "We believe that our intellectual property portfolio will provide our products with long-term market protection and will add significantly to our shareholder value."
These patents join eleven U.S. patents and twenty-eight foreign patents already obtained by Echo Therapeutics. Over 40 patent applications by Echo are pending in the U.S. and foreign countries.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2010, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:Christine OlimpioDirector, Corporate Communications215.717.4100
Connect With Us:- Visit our website at www.echotx.com- Follow us on Twitter at www.twitter.com/echotx- Join us on Facebook at www.facebook.com/echotx
SOURCE Echo Therapeutics, Inc.
Oil talked with Sutton about dignitaries
emailer to sutton about savwatt
Going to Grand Opening Friday. $$$$$$ coming!
Oil,
You must be way too important for dignitaries and even the head of SAVW to call you personally. You must trade millions of shares across the board. Yet, you have been in two whole penny stocks.
Why don't you try the NASDAQ or DOW?
Oh, and by the way PREZ OBAMA says HI!
Interesting times just around the corner.
Sell down to low $3's and then right back to $4.
Looking for a good week this week. I sense some news will be coming shortly.
We should be back to $5 land within a few weeks.
It moves slowly until news. Too expensive of a stock for the normal penny stock yahoos. FDA approval will come this year and stock will go to the moon.
IMHO
Steadily going back up. Looks like we will be ready for a much bigger jump when there is FDA news. Company is ready to rock and roll.
Getting ready for another good month!
Definitely, the approval will move the stock and the real move would be the next quarter (3rd quarter 2011) when the revenues are pouring in. That is why I am guessing a move to $5 for approval and 7.50 to $10 for later in the year.
IMHO
Best to read the link in the ibox as there should be approval in the second quarter and revenue coming in the third quarter. PPS will grow slowly and steadily till then.
ECTE had a huge run and pulled back with the market. This will easily go back to 4, 4+ when the market goes green again in the next week. Their system will gain approval in a month or so hopefully and then that should continue the climb.
It was a short term play, but it actually had great news and I expect it to go higher. It has a lot of institutional ownership and it will move when decent volume comes in. I found it on gorillatrades.com. They have some decent picks, but this was a quick do it yourself pick.
CEO of advfn was just on CNBC. What a TOOL!
Will be $9 by summer time
Looking good for another jump. Maybe 4.25 tommorow
you are probably right, but we could test resistance at $4 this week.
Looks like it is time to go on another run. BE READY
K, always such a help, Thanks for caring about GWAY and every other stock that goes up. You ever not short and help
Another solid day, building more strength.
AWESOME DAY!!